Respiratory-Gated Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract without Fiducial Markers
| Autor: | Makoto Sasaki, Satoko Asahi, Satoshi Kobayashi, Kazutaka Yamamoto, Yuji Tameshige, Hiroyasu Tamamura, Toshifumi Gabata, Satoshi Shibata, Mariko Kawamura, Miu Mizuhata, Yoshikazu Maeda, Tomoyasu Kumano, Sayuri Bou, Shigeyuki Takamatsu, Yoshitaka Sato |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
lcsh:RC254-282 Article 030218 nuclear medicine & medical imaging 4D-CT 03 medical and health sciences 0302 clinical medicine Ascites medicine proton beam therapy hepatocellular carcinoma gastrointestinal tract respiratory-gated irradiation Respiratory system Gastrointestinal tract Tumor size business.industry Common Terminology Criteria for Adverse Events medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Toxicity medicine.symptom business Nuclear medicine Fiducial marker |
| Zdroj: | Cancers, Vol 10, Iss 2, p 58 (2018) Cancers Cancers; Volume 10; Issue 2; Pages: 58 |
| ISSN: | 2072-6694 |
| Popis: | The efficacy of proton beam therapy (PBT) for hepatocellular carcinoma (HCC) has been reported, but insertion of fiducial markers in the liver is usually required. We evaluated the efficacy and toxicity of respiratory-gated PBT without fiducial markers for HCC located within 2 cm of the gastrointestinal tract. From March 2011 to December 2015 at our institution, 40 patients were evaluated (median age, 72 years; range, 38–87 years). All patients underwent PBT at a dose of 60 to 80 cobalt gray equivalents (CGE) in 20 to 38 fractions. The median follow-up period was 19.9 months (range, 1.2–72.3 months). The median tumor size was 36.5 mm (range, 11–124 mm). Kaplan–Meier estimates of the 2-year overall survival, progression-free survival, and local tumor control rates were 76%, 60%, and 94%, respectively. One patient (2.5%) developed a grade 3 gastric ulcer and one (2.5%) developed grade 3 ascites retention; none of the remaining patients developed grade >3 toxicities (National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.0.). This study indicates that PBT without fiducial markers achieves good local control without severe treatment-related toxicity of the gastrointestinal tract for HCC located within 2 cm of the gastrointestinal tract. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|